Analysts’ Viewpoint
Rise in demand for personalized medicine, technological advancements, expanding applications, and emergence of new regional markets are expected to drive the global cell analysis industry growth during the forecast period. Continuous evolution of cell analysis technologies and their integration into diverse research & clinical settings are likely to propel market expansion. This in turn would facilitate deeper insights into cellular biology and revolutionizing the diagnosis and treatment of various diseases.
Increase in healthcare expenditure and rise in research activities, especially in emerging economies, offer lucrative opportunities to market players. Companies are focusing on developing efficient and affordable personalized medicines using cell analysis in order to increase market share and presence.
The cell analysis industry encompasses a range of technologies, instruments, and software used for studying and analyzing cells. It plays a crucial role in various scientific and medical disciplines, enabling researchers and clinicians to gain insights into cellular behavior, functions, and interactions. The field of cell analysis has witnessed significant advancements in the past few years, driven by technological innovations and growing demand for more comprehensive cellular analysis.
Applications of cell analysis are diverse and span across multiple fields. In basic research, cell analysis helps unravel the intricacies of cellular biology, aiding in the understanding of fundamental cellular processes and mechanisms. It also plays a crucial role in drug discovery and development by facilitating target identification and validation, as well as assessing drug efficacy and toxicity.
Technology integration is a key driver of the cell analysis market growth. New technologies can be integrated with existing ones to create more powerful and accurate tools for researchers and healthcare professionals. Hence, there has been an increasing adoption of technology integration in cell analysis by players.
In May 2023, Deepcell, a company specializing in artificial intelligence (AI)-powered single cell analysis, launched the REM-I Platform, which includes benchtop instruments, the Axon data suite and the Human Foundation Model. This high-dimensional cell morphology analysis and sorting platform combines single cell sorting, imaging, and analysis to catalyze new approaches to discovery in fields such as developmental biology, stem cell biology, cancer biology, gene therapy, and functional screening. According to the company, their AI-powered approach to cellular analysis is anticipated to develop biological research, ushering in a new era of discovery.
In January 2023, Axion BioSystems expanded its Omni live-cell imaging product family with the introduction of the Omni Pro 12 platform. The new platform is equipped with integrated robotics and a multiplate design compatible with any standard incubator, providing scientists and drug developers with increased flexibility and efficiency for live-cell imaging experiments. The platform offers a valuable tool in advancing research in areas such as oncology, immunology, and stem cell biology. The technology has the potential to facilitate the development of novel drugs and therapeutics.
Technology integration enables researchers and healthcare professionals to collect and analyze cell data more efficiently and accurately, leading to improved diagnostic and therapeutic outcomes. It can also assist companies in optimizing profits through product development mergers.
Collaboration and partnerships have a significant impact on the cell analysis market dynamics. By working together, companies and organizations pool their resources, expertise, and technologies to develop new and innovative cell analysis tools and services. The synergy is likely to give a competitive edge to the players.
Several players enter into collaborations for product development or regional expansion in order to tap the lucrative cell analysis market opportunities. For instance, in February 2023, Ultima Genomics, Inc. partnered with 10x Genomics to integrate the use of 10x Genomics Chromium Single Cell Gene Expression offerings with Ultima's sequencing systems. This collaboration, as part of the 10x Compatible Partner Program, aims to provide researchers with more efficient, cost-effective workflows for studying gene expression in single cells at a larger scale. By leveraging 10x Genomics' Single Cell offerings, researchers can gain a deeper understanding of the intricacies of biology on a cellular level through various applications.
Similarly, in March 2023, Becton Dickinson Holdings Pte. Ltd. (BD) announced an extension of its research partnership with the Agency for Science, Technology, and Research. The partnership aims to use spectral flow cytometry panels for deep immunophenotyping of human tissues, leveraging the latest advancements in technology, such as the BD FACSymphony A5 SE Cell Analyzer unit. The collaboration seeks to uncover new discoveries that can lead to improved healthcare outcomes by identifying novel insights through advanced immunophenotyping techniques.
Hence, collaboration and partnerships could drive innovation, accelerate development, and increase the impact of cell analysis growth by leveraging the strengths and resources of multiple companies and organizations.
In terms of end-user, the biotechnology & pharmaceutical companies segment is projected to account for the largest global cell analysis market share from 2023 to 2031.
Emergence of new treatments, advancements in medical devices, and innovations across various sectors offer significant market opportunities for cell analysis companies. Additionally, the shift in scientific focus toward addressing new diseases has contributed to the expansion of the segment. Moreover, governments and private organizations are investing significantly in research & development efforts to discover novel solutions.
Based on therapeutic area, the oncology & immune-oncology segment dominated the market in 2022. The nucleic acid-based drugs sub-segment of the oncology & immune-oncology segment is anticipated to expand at a high CAGR from 2023 to 2031.
Single-cell technologies of cell analysis are emerging as potent instruments in cancer research. These advanced tools allow molecular profiling of individual cells within a tumor, opening up new avenues for studying tumor heterogeneity, and the composition of cell types in the microenvironment. Rise in adoption of new technology for cell analysis is likely to increase the oncology & immune-oncology segment’s market share.
Based on technology, the flow cytometry segment is likely to account for leading share in 2022. Flow cytometry is a rapid technology used to analyze individual cells as it pass by one or numerous lasers while suspended in a buffered salt-based solution.
Availability of a greater variety of reagents in the past few years has resulted in exponential increase in the number of parameters used in experiments of flow cytometry. The market has witnessed significant rise in the use of fluorochromes, such as polymer dyes and tandem dyes, for conjugating monoclonal antibodies.
The cell analysis workplace plays a crucial role in each stage of the drug discovery and development process. By utilizing various cell analysis techniques, in vitro preclinical studies contribute to the understanding of drug candidates' efficacy, toxicity, MOA, and formulation, thus informing decision-making for further development and advancing the most promising candidates to in vivo preclinical and clinical studies. These advanced cell analysis techniques contribute to the efficiency and success of drug development efforts.
As per cell analysis market trends, the U.S. dominated the global industry, with largest share in 2022. The trend is projected to continue during the forecast period. This can be ascribed to growth in cell cycle analysis, strong presence of key players, and increase in demand for cell therapy.
In October 2022, Century Therapeutics and Bristol Myers Squibb announced a research collaboration and license agreement aimed at developing and commercializing up to four programs for hematologic malignancies and solid tumors. The collaboration brings together Century's leading iPSC-based allogeneic cell therapy platform and Bristol Myers Squibb's knowledge in cell therapy and oncology drug development.
| Attribute | Detail |
|---|---|
|
Size in 2022 |
US$ 19.0 Bn |
|
Forecast (Value) in 2031 |
More than US$ 42.4 Bn |
|
Growth Rate (CAGR) |
9.2% |
|
Forecast Period |
2023-2031 |
|
Historical Data Available for |
2017-2022 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, and R&D overview. |
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
It was valued at US$ 19.0 Bn in 2022
It is projected to reach US$ 42.4 Bn by 2031
It expanded at a CAGR of 10.9% from 2017 to 2022
It is likely to advance at a CAGR of 9.2% from 2023 to 2031
Increase in collaboration & partnerships among players, technology integration in cell analysis, surge in funding for cell analysis research, and rise in demand for point-of-care.
The biotechnology & pharmaceutical companies segment held around 48.0% share in 2022
The U.S. is expected to be highly lucrative region during the forecast period.
1. Preface
1.1. Market Definition and Scope
1.2. Key Research Objectives
2. Assumptions and Research Methodology
3. Market Overview
3.1. Overview
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Overview on R&D spending of major biotechnology and pharmaceutical companies by therapeutic area
3.3.1. Top 15 Origins of Pipeline Drugs
3.3.2. Biological versus non-biological drugs as a % of pipeline
3.3.3. Ongoing rise of gene and cell therapy
4. Global Cell Analysis Market Analysis and Forecast, by End-user
4.1. Introduction & Definition
4.2. Key Findings/Developments
4.3. Market Value Forecast, by End-user, 2017-2031
4.3.1. Biotechnology & Pharmaceutical Companies
4.3.2. Academia
4.3.3. Cosmetic Industry
4.3.4. Contract Research Organizations
4.3.5. Contract Development and Manufacturing Organizations
5. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Therapeutic Area
5.1. Introduction & Definition
5.2. Key Findings/Developments
5.3. Market Value Forecast, by Therapeutic Area, 2015-2031
5.3.1. Oncology & Immune-oncology
5.3.1.1. Small Molecules
5.3.1.2. Protein-based Therapeutics
5.3.1.3. Cell Therapy
5.3.1.4. Nucleic Acid-based Drugs
5.3.2. Cardiovascular & Metabolic Diseases
5.3.2.1. Small Molecules
5.3.2.2. Protein-based Therapeutics
5.3.2.3. Cell Therapy
5.3.2.4. Nucleic Acid-based Drugs
5.3.3. Immunology
5.3.3.1. Small Molecules
5.3.3.2. Protein-based Therapeutics
5.3.3.3. Cell Therapy
5.3.3.4. Nucleic Acid-based Drugs
5.3.4. Rare Diseases
5.3.4.1. Small Molecules
5.3.4.2. Protein-based Therapeutics
5.3.4.3. Cell Therapy
5.3.4.4. Nucleic Acid-based Drugs
5.3.5. Neurological Diseases
5.3.5.1. Small Molecules
5.3.5.2. Protein-based Therapeutics
5.3.5.3. Cell Therapy
5.3.5.4. Nucleic Acid-based Drugs
5.3.6. Others
5.3.6.1. Small Molecules
5.3.6.2. Protein-based Therapeutics
5.3.6.3. Cell Therapy
5.3.6.4. Nucleic Acid-based Drugs
6. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Technology
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Technology, 2017-2031
6.3.1. Flow Cytometry
6.3.2. Image-based Cytometry
6.3.3. Biochemical Assays
6.3.4. Mass Spectrometry
7. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Workplace
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Workplace, 2017-2031
7.3.1. Target Identification
7.3.2. Hit Generation & Lead Identification
7.3.3. Lead Optimization
7.3.4. In Vitro Preclinical Studies
7.3.5. In Vivo Preclinical Studies
7.3.6. Clinical Studies
8. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Country/Region
8.1. Key Findings
8.2. Market Value Forecast, by Country/Region, 2017-2031
8.2.1. U.S.
8.2.2. Europe
8.2.3. China
8.2.4. Rest of the World
9. U.S. Cell Analysis Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by End-user, 2017-2031
9.2.1. Biotechnology & Pharmaceutical Companies
9.2.2. Academia
9.2.3. Cosmetic Industry
9.2.4. Contract Research Organizations
9.2.5. Contract Development and Manufacturing Organizations
9.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
9.3.1. Oncology & Immune-oncology
9.3.1.1. Small Molecules
9.3.1.2. Protein-based Therapeutics
9.3.1.3. Cell Therapy
9.3.1.4. Nucleic Acid-based Drugs
9.3.2. Cardiovascular & Metabolic Diseases
9.3.2.1. Small Molecules
9.3.2.2. Protein-based Therapeutics
9.3.2.3. Cell Therapy
9.3.2.4. Nucleic Acid-based Drugs
9.3.3. Immunology
9.3.3.1. Small Molecules
9.3.3.2. Protein-based Therapeutics
9.3.3.3. Cell Therapy
9.3.3.4. Nucleic Acid-based Drugs
9.3.4. Rare Diseases
9.3.4.1. Small Molecules
9.3.4.2. Protein-based Therapeutics
9.3.4.3. Cell Therapy
9.3.4.4. Nucleic Acid-based Drugs
9.3.5. Neurological Diseases
9.3.5.1. Small Molecules
9.3.5.2. Protein-based Therapeutics
9.3.5.3. Cell Therapy
9.3.5.4. Nucleic Acid-based Drugs
9.3.6. Others
9.3.6.1. Small Molecules
9.3.6.2. Protein-based Therapeutics
9.3.6.3. Cell Therapy
9.3.6.4. Nucleic Acid-based Drugs
9.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
9.4.1. Flow Cytometry
9.4.2. Image-based Cytometry
9.4.3. Biochemical Assays
9.4.4. Mass Spectrometry
9.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
9.5.1. Target Identification
9.5.2. Hit Generation & Lead Identification
9.5.3. Lead Optimization
9.5.4. In Vitro Preclinical Studies
9.5.5. In Vivo Preclinical Studies
9.5.6. Clinical Studies
10. Europe Cell Analysis Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by End-user, 2017-2031
10.2.1. Biotechnology & Pharmaceutical Companies
10.2.2. Academia
10.2.3. Cosmetic Industry
10.2.4. Contract Research Organizations
10.2.5. Contract Development and Manufacturing Organizations
10.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
10.3.1. Oncology & Immune-oncology
10.3.1.1. Small Molecules
10.3.1.2. Protein-based Therapeutics
10.3.1.3. Cell Therapy
10.3.1.4. Nucleic Acid-based Drugs
10.3.2. Cardiovascular & Metabolic Diseases
10.3.2.1. Small Molecules
10.3.2.2. Protein-based Therapeutics
10.3.2.3. Cell Therapy
10.3.2.4. Nucleic Acid-based Drugs
10.3.3. Immunology
10.3.3.1. Small Molecules
10.3.3.2. Protein-based Therapeutics
10.3.3.3. Cell Therapy
10.3.3.4. Nucleic Acid-based Drugs
10.3.4. Rare Diseases
10.3.4.1. Small Molecules
10.3.4.2. Protein-based Therapeutics
10.3.4.3. Cell Therapy
10.3.4.4. Nucleic Acid-based Drugs
10.3.5. Neurological Diseases
10.3.5.1. Small Molecules
10.3.5.2. Protein-based Therapeutics
10.3.5.3. Cell Therapy
10.3.5.4. Nucleic Acid-based Drugs
10.3.6. Others
10.3.6.1. Small Molecules
10.3.6.2. Protein-based Therapeutics
10.3.6.3. Cell Therapy
10.3.6.4. Nucleic Acid-based Drugs
10.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
10.4.1. Flow Cytometry
10.4.2. Image-based Cytometry
10.4.3. Biochemical Assays
10.4.4. Mass Spectrometry
10.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
10.5.1. Target Identification
10.5.2. Hit Generation & Lead Identification
10.5.3. Lead Optimization
10.5.4. In Vitro Preclinical Studies
10.5.5. In Vivo Preclinical Studies
10.5.6. Clinical Studies
10.6. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Country/Sub-region, 2017-2031
10.6.1. EU5
10.6.2. U.K.
10.6.3. Switzerland
10.6.4. Rest of Europe
11. China Cell Analysis Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by End-user, 2017-2031
11.2.1. Biotechnology & Pharmaceutical Companies
11.2.2. Academia
11.2.3. Cosmetic Industry
11.2.4. Contract Research Organizations
11.2.5. Contract Development and Manufacturing Organizations
11.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
11.3.1. Oncology & Immune-oncology
11.3.1.1. Small Molecules
11.3.1.2. Protein-based Therapeutics
11.3.1.3. Cell Therapy
11.3.1.4. Nucleic Acid-based Drugs
11.3.2. Cardiovascular & Metabolic Diseases
11.3.2.1. Small Molecules
11.3.2.2. Protein-based Therapeutics
11.3.2.3. Cell Therapy
11.3.2.4. Nucleic Acid-based Drugs
11.3.3. Immunology
11.3.3.1. Small Molecules
11.3.3.2. Protein-based Therapeutics
11.3.3.3. Cell Therapy
11.3.3.4. Nucleic Acid-based Drugs
11.3.4. Rare Diseases
11.3.4.1. Small Molecules
11.3.4.2. Protein-based Therapeutics
11.3.4.3. Cell Therapy
11.3.4.4. Nucleic Acid-based Drugs
11.3.5. Neurological Diseases
11.3.5.1. Small Molecules
11.3.5.2. Protein-based Therapeutics
11.3.5.3. Cell Therapy
11.3.5.4. Nucleic Acid-based Drugs
11.3.6. Others
11.3.6.1. Small Molecules
11.3.6.2. Protein-based Therapeutics
11.3.6.3. Cell Therapy
11.3.6.4. Nucleic Acid-based Drugs
11.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
11.4.1. Flow Cytometry
11.4.2. Image-based Cytometry
11.4.3. Biochemical Assays
11.4.4. Mass Spectrometry
11.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
11.5.1. Target Identification
11.5.2. Hit Generation & Lead Identification
11.5.3. Lead Optimization
11.5.4. In Vitro Preclinical Studies
11.5.5. In Vivo Preclinical Studies
11.5.6. Clinical Studies
12. Rest of the World Cell Analysis Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by End-user, 2017-2031
12.2.1. Biotechnology & Pharmaceutical Companies
12.2.2. Academia
12.2.3. Cosmetic Industry
12.2.4. Contract Research Organizations
12.2.5. Contract Development and Manufacturing Organizations
12.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
12.3.1. Oncology & Immune-oncology
12.3.1.1. Small Molecules
12.3.1.2. Protein-based Therapeutics
12.3.1.3. Cell Therapy
12.3.1.4. Nucleic Acid-based Drugs
12.3.2. Cardiovascular & Metabolic Diseases
12.3.2.1. Small Molecules
12.3.2.2. Protein-based Therapeutics
12.3.2.3. Cell Therapy
12.3.2.4. Nucleic Acid-based Drugs
12.3.3. Immunology
12.3.3.1. Small Molecules
12.3.3.2. Protein-based Therapeutics
12.3.3.3. Cell Therapy
12.3.3.4. Nucleic Acid-based Drugs
12.3.4. Rare Diseases
12.3.4.1. Small Molecules
12.3.4.2. Protein-based Therapeutics
12.3.4.3. Cell Therapy
12.3.4.4. Nucleic Acid-based Drugs
12.3.5. Neurological Diseases
12.3.5.1. Small Molecules
12.3.5.2. Protein-based Therapeutics
12.3.5.3. Cell Therapy
12.3.5.4. Nucleic Acid-based Drugs
12.3.6. Others
12.3.6.1. Small Molecules
12.3.6.2. Protein-based Therapeutics
12.3.6.3. Cell Therapy
12.3.6.4. Nucleic Acid-based Drugs
12.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
12.4.1. Flow Cytometry
12.4.2. Image-based Cytometry
12.4.3. Biochemical Assays
12.4.4. Mass Spectrometry
12.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
12.5.1. Target Identification
12.5.2. Hit Generation & Lead Identification
12.5.3. Lead Optimization
12.5.4. In Vitro Preclinical Studies
12.5.5. In Vivo Preclinical Studies
12.5.6. Clinical Studies
List of Tables
Table 01: Overview on R&D spending of major biotechnology and pharmaceutical companies, by therapeutic areas (1/4)
Table 02: Overview on R&D spending of major biotechnology and pharmaceutical companies, by therapeutic areas (2/4)
Table 03: Overview on R&D spending of major biotechnology and pharmaceutical companies, by therapeutic areas (2/3)
Table 04: Overview on R&D spending of major biotechnology and pharmaceutical companies, by therapeutic areas (4/4)
Table 05: Top 15 Origins of Pipeline Drugs
Table 06: Global Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 07: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
Table 08: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
Table 09: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
Table 10: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
Table 11: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
Table 12: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
Table 13: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
Table 14: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 15: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
Table 16: Global Cell Analysis Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 17: U.S. Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 18: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
Table 19: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
Table 20: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
Table 21: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
Table 22: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
Table 23: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
Table 24: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
Table 25: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 26: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
Table 27: Europe Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 28: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
Table 29: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
Table 30: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
Table 31: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
Table 32: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
Table 33: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
Table 34: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
Table 35: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 36: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
Table 37: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 38: China Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 39: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
Table 40: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
Table 41: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
Table 42: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
Table 43: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
Table 44: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
Table 45: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
Table 46: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 47: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
Table 48: Rest of the World Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 49: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
Table 50: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
Table 51: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
Table 52: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
Table 53: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
Table 54: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
Table 55: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
Table 56: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 57: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
List of Figures
Figure 01: Major R&D spending therapeutic areas, by companies
Figure 02: Biological versus non-biological drugs as a % of pipeline
Figure 03: Ongoing rise of gene and cell therapy
Figure 04: Global Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
Figure 05: Global Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
Figure 06: Global Cell Analysis Market (US$ Mn), by Biotechnology & Pharmaceutical Companies, 2017-2031
Figure 07: Global Cell Analysis Market (US$ Mn), by Academia, 2017-2031
Figure 08: Global Cell Analysis Market (US$ Mn), by Cosmetic Industry, 2017-2031
Figure 09: Global Cell Analysis Market (US$ Mn), by Contract Research Organizations, 2017-2031
Figure 10: Global Cell Analysis Market (US$ Mn), by Contract Development and Manufacturing Organizations, 2017-2031
Figure 11: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 12: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
Figure 13: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Oncology & Immune-oncology, 2017-2031
Figure 14: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Cardiovascular & Metabolic Diseases, 2017-2031
Figure 15: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Immunology, 2017-2031
Figure 16: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Rare Diseases, 2017-2031
Figure 17: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Neurological Diseases, 2017-2031
Figure 18: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Others, 2017-2031
Figure 19: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Technology, 2022 and 2031
Figure 20: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Technology, 2023-2031
Figure 21: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Flow Cytometry, 2017-2031
Figure 22: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Image-based Cytometry/Microscopy, 2017-2031
Figure 23: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Biochemical Assays, 2017-2031
Figure 24: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Mass Spectrometry, 2017-2031
Figure 25: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Workplace, 2022 and 2031
Figure 26: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
Figure 27: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Target Identification, 2017-2031
Figure 28: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Hit Generation & Lead Identification, 2017-2031
Figure 29: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Lead Optimization, 2017-2031
Figure 30: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by In Vitro Preclinical Studies, 2017-2031
Figure 31: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by In Vivo Preclinical Studies, 2017-2031
Figure 32: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Clinical Studies, 2017-2031
Figure 33: Global Cell Analysis Market Value Share Analysis, by Region, 2022 and 2031
Figure 34: Global Cell Analysis Market Attractiveness Analysis, by Region, 2023-2031
Figure 35: U.S. Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031
Figure 36: U.S. Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
Figure 37: U.S. Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
Figure 38: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 39: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
Figure 40: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Technology, 2022 and 2031
Figure 41: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Technology, 2023-2031
Figure 42: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031
Figure 43: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
Figure 44: Europe Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031
Figure 45: Europe Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
Figure 46: Europe Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
Figure 47: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 48: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
Figure 49: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Technology, 2022 and 2031
Figure 50: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Technology, 2023-2031
Figure 51: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031
Figure 52: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
Figure 53: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 54: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 55: China Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031
Figure 56: China Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
Figure 57: China Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
Figure 58: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 59: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
Figure 60: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Technology, 2022 and 2031
Figure 61: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Technology, 2023-2031
Figure 62: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031
Figure 63: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
Figure 64: Rest of the World Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031
Figure 65: Rest of the World Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
Figure 66: Rest of the World Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
Figure 67: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 68: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
Figure 69: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Technology, 2022 and 2031
Figure 70: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Technology, 2023-2031
Figure 71: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031
Figure 72: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Cell Analysis Market
